MMB for Myelofibrosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to provide ongoing access to momelotinib for patients with certain types of myelofibrosis who are already taking the drug and have not seen their disease get worse. The study will also look at how long these patients live without developing leukemia. Momelotinib has been studied for myelofibrosis and other related conditions.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on participants already receiving momelotinib, so it's best to discuss your specific situation with the trial coordinators.
Is Momelotinib safe for humans?
Momelotinib has been studied in many patients with myelofibrosis, and common side effects include diarrhea, low platelet counts, and anemia. Serious side effects like infections or nerve problems did not increase over time, and the safety profile was consistent without long-term issues. Dose adjustments may be needed for people with severe liver problems.12345
How is the drug Momelotinib unique in treating myelofibrosis?
Momelotinib is unique because it not only targets JAK1 and JAK2 like other treatments but also inhibits ACVR1, which helps address anemia and reduces the need for blood transfusions in myelofibrosis patients. This makes it particularly beneficial for patients with anemia, a common issue with other JAK inhibitors.13567
What data supports the effectiveness of the drug Momelotinib for treating myelofibrosis?
Who Is on the Research Team?
GSK Clinical Trials
Principal Investigator
GlaxoSmithKline
Are You a Good Fit for This Trial?
This trial is for adults with myelofibrosis who are already participating in specific earlier studies of momelotinib (MMB). They must understand and agree to the study's terms. People allergic to MMB or its ingredients cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Extended Access Treatment
Participants continue to receive momelotinib as per their previous study regimen until regulatory approval or cessation of product development
Follow-up
Participants are monitored for overall survival and leukemia-free survival
What Are the Treatments Tested in This Trial?
Interventions
- Momelotinib
Momelotinib is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sierra Oncology LLC - a GSK company
Lead Sponsor
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
Sierra Oncology, Inc.
Lead Sponsor